Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive    source : Www.immunogen.com    save search
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Published: 2021-12-12 (Crawled : 16:20) - immunogen.com
IMGN | $31.23 0.03% 49M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
imgn632 myeloid leukemia phase 1b leukemia phase 1 positive acute myeloid leukemia phase 2b
Gainers vs Losers
67% 33%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.